Crotamiton pharma grade API is supplied as a pale yellowish oily liquid for tablet, capsule, granule, and injection development; however, current compendial monographs and approved finished drug products are confined to topical semisolid and liquid preparations. Oral and injectable finished drugs have no established commercial formula or published industrial batch data, and tablet/capsule/granule/injection processing is therefore excluded from the downstream application matrix to avoid unverifiable application claims. The scenarios below represent only the substance's validated topical downstream tracks, drawn from approved crotamiton formulations and nonsterile compounding practice.

The active has a molecular weight of 203.28 g/mol and is practically insoluble in water while being miscible with ethanol, ether, chloroform, and many fatty esters. Density at 20°C is approximately 0.987 g/cm³, and boiling point at 13 hPa is 168–170°C. This partition behavior controls the addition point, pump selection, and vessel cleaning in all downstream operations.

Phase-Transfer Parameters for a 10% w/w Crotamiton Scabicidal Cream

The standard addition ratio in an oil-in-water scabicidal cream is 10% w/w crotamiton. The active is not metered as a neat liquid directly into the finished aqueous batch; it is first dissolved in the lipophilic phase consisting of cetostearyl alcohol, liquid paraffin, white petrolatum, and nonionic emulsifying wax. The lipophilic phase is heated to 70–75°C in a jacketed stainless-steel vessel under low-shear anchor agitation at 20–30 rpm, and crotamiton is introduced when the oil phase reaches 65°C to prevent localized viscosity stratification. The water phase is separately heated to 70–75°C and contains glycerin and preservative agents. Both phases are combined in a vacuum emulsifying mixer at -0.06 MPa internal pressure; a rotor-stator homogenizer operates at 2,500–3,500 rpm for 15 min, after which cooling proceeds to 30–35°C under side-scraper agitation at 15–25 rpm.

In-process testing includes droplet size D90 below 20 µm by laser diffraction after 10 min of homogenization and viscosity in the range of 40,000–80,000 mPa·s at 25°C using a Brookfield RV helipath spindle T-C at 5 rpm. Air entrapment is the most frequent production-scale failure mode when vacuum release is executed before complete degassing; the resulting cream shows bubble-nucleated pinholes in tube fill. Compliance is governed by 21 CFR 210/211, USP <61> and USP <62> for nonsterile microbial limits, USP <51> for preservative effectiveness, and ICH Q3D for elemental impurities. Finished product types are epoxy-lined aluminum or plastic tubes of 30 g, 60 g, and 100 g.

A hydroalcoholic crotamiton lotion is formulated at 10% w/w active with an ethanol content of 30–50% w/w, purified water, propylene glycol, and a rheology modifier such as hydroxyethylcellulose or neutralized carbomer. The manufacturing sequence starts with the preparation of a crotamiton-ethanol solution in a closed, explosion-proof stainless-steel mixer purged with nitrogen at 0.5 bar gauge; because the active is miscible with ethanol, this stage requires no high-shear dispersion. The solution is then slowly charged into the aqueous phase at 20–25°C with a variable-speed turbine at 300–600 rpm, and the neutralized carbomer dispersion is added afterward to avoid permanently destroying the yield value of the polymer network through excessive shear.

Final lotion viscosity is adjusted to 1,500–3,000 mPa·s at 25°C using a Brookfield RVT spindle 5 at 20 rpm, and the product is filled into amber PET or HDPE bottles of 60 mL and 100 mL with a dropper or metered-dose pump. Safety compliance for ethanol handling follows ATEX 2014/34/EU or equivalent local explosion-protection requirements, while drug product manufacture is conducted under 21 CFR 210/211; microbial enumeration follows USP <61> and USP <62>. Residual ethanol is controlled under ICH Q3C as a Class 3 solvent. The addition ratio of 10% w/w is aligned with commercial dry-skin scabicidal lotion formulations.

What Cooling Protocol Prevents Mottling in Anhydrous Crotamiton Ointment?

An anhydrous crotamiton ointment is produced at 10% w/w in a lipophilic base of white petrolatum, liquid paraffin, paraffin wax, and wool alcohols. Process control centers on the cooling curve rather than emulsification because crotamiton remains soluble in the molten paraffin-petrolatum mixture only while the temperature is maintained above 40°C; when the batch cools below this threshold without continuous scraped-surface mixing, the base can form high-viscosity bands and surface mottling that are visible in the finished jar. The manufacturing sequence uses a planetary mixer with steel scrapers at 25–35 rpm; the waxes and petrolatum are melted at 70–75°C, crotamiton is added at 65°C, and the batch is cooled to 40°C at 0.5–1.0°C/min before being passed through a colloid mill with a 200 µm gap setting.

The primary production-scale defect associated with this form is cold-wall fouling on the jacketed vessel if the temperature differential between the cooling water and the product exceeds 5–10°C; this fouling can produce hard wax agglomerates that are not eliminated by the colloid mill. Compliance for commercial manufacture is under 21 CFR 210/211; for extemporaneous preparation, USP <795> and ISO 14644-1:2015 Class 8 or better controlled-area classification apply. Nonsterile microbial limits are tested according to USP <61> and USP <62>. Terminal product types include aluminum tubes of 30 g, 60 g, and pharmacy dispensing jars up to 500 g.

Low-viscosity oil-in-water crotamiton lotion is distinguished from the cream format by a reduced internal lipid phase, typically 8–15% w/w total oil phase, while the active concentration remains 10% w/w. Crotamiton is pre-dissolved in the oil phase at 60–65°C before the oil and water phases are combined in a vacuum vessel equipped with a bottom-entry rotor-stator disperser at 1,800–2,500 rpm. The lower lipid content means the emulsion is less tolerant of temperature overshoot; if the combined phase temperature falls below 45°C before homogenization starts, the primary emulsion forms with coarse droplets that cannot be corrected by later cooling. After initial high-shear mixing for 8–12 min, the batch is cooled to 25–30°C under low-shear sweep agitation at 10–20 rpm.

Viscosity is adjusted with a polymeric thickener to 500–1,500 mPa·s at 25°C using a Brookfield LV spindle 2 at 30 rpm. The production-scale batch record should verify that the distributor is not run at full speed after thickener addition because shear-thinning causes variable fill weight on the rotary piston filler. The lotion is filled into 120 mL and 200 mL HDPE bottles with a washable pump. Compliance includes 21 CFR 210/211, USP <61>/<62>, and ICH Q3D; if the lotion is packaged as a multi-dose container, preservative efficacy must meet USP <51> acceptance criteria. This O/W lotion format is used when a more spreadable film is required over large body surfaces.

When Extemporaneous Nonsterile Compounding Requires Reduced Crotamiton Concentration in Pediatric Practice

In extemporaneous nonsterile compounding, crotamiton pharma-grade API is incorporated into a buffered cream base at 5% w/w or 10% w/w according to prescription; the 5% w/w concentration is selected for pediatric use or for application to intertriginous skin when reduced local exposure is required. The preparation starts by wetting the active with a minimal volume of light mineral oil or propylene glycol, then levigating the wetted active into a measured quantity of cream base on an electric ointment mill. Minimum trituration time is 3 min; the product is passed through the mill at a gap setting of 100–150 µm to disperse the active uniformly before packaging.

Compounding is performed under USP <795> and in an ISO 14644-1:2015 Class 8 or better controlled area; personnel use non-shedding gowns and stainless-steel equipment cleaned with 70% v/v isopropanol. In-use stability beyond the beyond-use date of 30 days for aqueous creams at controlled room temperature is not recommended. Finished product types are light-resistant ointment jars or syringes of 30 g to 120 g. The most frequent compounding failure is active partitioning at the base surface; this is controlled by restricting the initial wetting volume to 1:1 with the active weight and avoiding direct addition to the jar before levigation.